MINDACT trial: genomic profiling shows chemotherapy is unnecessary in half of women with breast cancer

Updated results of the Phase III MINDACT trial, previously reported at the ASCO Annual Meeting 2020 (29–31 May) and 2020 San Antonio Breast Cancer Symposium (8–11 December), have recently been published in the Lancet Oncology. The results are very encouraging and suggest genomic profiling accurately identifies where de-escalation of chemotherapy is possible in breast cancer patients. The MINDACT trial (NCT00433589) begun in December of 2006 and accrued 6693 female patients with breast cancer involving no more than three lymph nodes. The trial sought to investigate the accuracy of genomic profiling compared with clinical assessment in determining the need for chemotherapy...